The Pseudomonas aeruginosa-derived phenazine pigments pyocyanin and 1-hydroxyphenazine (1-hp) prime human neutrophils for enhanced, stimulus-activated release of superoxide and myeloperoxidase (MPO), respectively. In the present study, the modulatory potentials of the antimicrobial agents clindamycin, eythromycin, and roxithromycin (10 and 20 ,ug/ml) on the prooxidative interactions of pyocyanin and 1-hp (12.5 FM) with human neutrophils have been investigated. Clindamycin, erythromycin, and especially roxithromycin caused dose-related inhibition of the generation of superoxide by both untreated and pyocyanin-treated neutrophils during activation with either the synthetic chemotactic tripeptide N-formyl-Lmethionyl-L-leucyl-L-phenylalanine (FMLP) or the calcium ionophore A23187. The antimicrobial agents also inhibited the generation of reactive oxidants by the MPO-H202-halide system during activation of both untreated and 1-hp-treated neutrophils by FMLP. These effects appeared to be due to drug-related interference with membrane-associated oxidative metabolism, since none of the antimicrobial agents inhibited the release of MPO by activated neutrophils, nor did they possess oxidant-scavenging properties. These data demonstrate that clindamycin, erythromycin, and especially roxithromycin antagonize the proinflammatory interactions of pyocyanin and 1-hp with neutrophils and indicate a possible therapeutic role for these antimicrobial agents in the prevention of tissue damage in diseases characterized by P. aeruginosa infection.
The Pseudomonas aeruginosa-derived phenazine pigment pyocyanin, at pathologically relevant concentrations, primes human neutrophils for increased oxygen consumption and increased generation of superoxide when the cells are subsequently exposed to stimuli of membrane-associated oxidative metabolism (25, 31) . The prooxidative potential of pyocyanin is amplified by its degradation product, 1-hydroxyphenazine (1-hp) , which is also synthesized byP. aeruginosa and which primes neutrophils for enhanced release of myeloperoxidase (MPO) (31) . Pigment-neutrophil interaction during P. aeruginosa infection may cause reactive oxidantmediated damage to host tissues, particularly during chronic colonization of the bronchial tree in bronchiectasis. In this situation, damage to the bronchial epithelium may be inflicted by prolonged exposure to oxidants and proteases released by chronically activated phagocytes (6, 7, 21) . Moreover, in patients with P. aeruginosa pneumonia, pulmonary parenchymal destruction might also be related to the release of oxidants and granule enzymes by pigment-primed hyperactive neutrophils (9, 17, 28) .
Broad-spectrum antibiotic treatment with currently available agents is insufficient to eradicate P. aeruginosa from the bronchial tree of patients with bronchiectasis and cystic fibrosis once colonization has occurred (19) . Inhibition of the reactive-oxidant component of neutrophil-induced chronic bronchial inflammation might therefore introduce a new * Corresponding author.
strategy to prevent progressive tissue damage in bronchiectasis. The lysosomotropic, weakly basic antimicrobial agents clindamycin, erythromycin, and roxithromycin, which accumulate in phagocytes, have previously been shown to inhibit superoxide generation by activated neutrophils at therapeutic and supratherapeutic concentrations in vitro (1, 16, 18, 32) . In the present study, we have investigated the effects of these agents on the potentially harmful prooxidative interactions of pyocyanin and 1-hp with human neutrophils in vitro. Superoxide generation by neutrophils. Superoxide was determined by measuring the superoxide dismutase-inhibitable reduction of ferricytochrome c in a final reaction volume of 1 ml (4). Neutrophils (106/ml) were preincubated for 45 min with or without roxithromycin, erythromycin, and clindamycin (10 and 20 ,ug/ml) at room temperature. This procedure was included to prevent the loss of responsiveness of neutrophils to the N-formyl-L-methionyl-L-leucyl-Lphenylalanine (FMLP)-activated superoxide generation which occurs during prolonged preincubation of the cells at 37°C (1) . Pyocyanin (12.5 aiM) or an equal volume of HBSS was added, the reaction mixture was incubated for 5 min at 37°C, and 0.1 mM cytochrome c (type VI from horse heart) was added. Superoxide generation was initiated by the addition of the stimulant FMLP (1 ,M) or calcium ionophore A23187 (1 ,uM) and was stopped after 5 min with 4 ml of ice-cold phosphate-buffered saline. Neutrophils were pelleted by centrifugation, and the optical density of the supernatant fluid was measured at 550 nm in a UV spectrophotometer (model SP1700; Pye Unicam, Cambridge, United Kingdom). The amount of reduced cytochrome c was calculated by using a molar extinction coefficient of 2.11 x 104 cm2/mmol (33) . Superoxide-mediated reduction of cytochrome c was calculated as the difference in optical density between reaction mixtures with and without superoxide dismutase, and the results are expressed as nanomoles of reduced cytochrome c per 106 neutrophils. We have previously reported that pyocyanin and 1-hp (12.5 ,uM), as well as erythromycin and roxithromycin at concentrations of up to 20 ,ug/ml, do not scavenge superoxide (1, 31) . In the present study, the effects of clindamycin (20 ,ug/ml) on the generation of superoxide by a cell-free hypoxanthine (500 ,uM) and xanthine oxidase (50 mU/ml) were investigated to control for possible scavenging of superoxide by the antimicrobial agent.
MATERIALS AND METHODS

Unless
Oxygen consumption by human neutrophils. Oxygen consumption was measured with a three-channel oxygen electrode (model DWI; Hansatech, Norfolk, United Kingdom). Neutrophils (2 x 106) in 1 ml of HBSS were preincubated with or without roxithromycin (20 ,ug/ml) for 45 min at room temperature. Neutrophils were then brought to 37°C, and pyocyanin (25 ,uM) or an equal volume of HBSS was added. MPO-mediated iodination. Neutrophils (106/ml) were preincubated with or without roxithromycin, erythromycin, and clindamycin (10 and 20 ,ug/ml) for 45 min at room temperature. 1-hp (12.5 ,uM) was added to appropriate tubes, and the cells were incubated for 5 min at 37°C in HBSS containing 0.6 ,uCi of Na125I (specific activity, 17 Ci/mg) and 40 nmol of carrier Nal in 900 ,ul of HBSS. MPO-mediated iodination was then activated by the addition of FMLP (1 ,uM) . After (27) . The by the xanthine oxidase-hypoxanthine system (data not shown).
Effects of roxithromycin on oxygen consumption by control and pyocyanin-treated, FMLP-activated neutrophils. The effects of roxithromycin on pyocyanin-treated, FMLP-activated neutrophils are shown in Table 2 . Roxithromycin at 20 ,ug/ml caused significant inhibition of oxygen consumption by neutrophils activated with FMLP in the presence of 25 ,uM pyocyanin at 10 and 20 min (P < 0.01) after the addition of FMLP.
Effects of the antimicrobial agents on MPO-mediated iodination by control and 1-hp-treated, FMLP-activated neutrophils. The effects of the antimicrobial agents on MPOmediated iodination are shown in Table 3 . Clindamycin, erythromycin, and roxithromycin at 10 and 20 ,ug/ml caused significant inhibition of MPO-mediated iodination of neutrophils activated with FMLP in the absence and presence of 12.5 p,M 1-hp. The order of potency was roxithromycin > erythromycin (P < 0.05) and roxithromycin > clindamycin (P < 0.05). None of the test agents at a fixed concentration of 20 ,ug/ml inhibited the iodination of bovine serum albumin by a cell-free glucose-glucose oxidase-horseradish peroxidase system (data not shown).
Effects of roxithromycin on neutrophil degranulation by control and 1-hp-treated, FMLP-CB-activated neutrophils.
Roxithromycin at 10 and 20 p,g/ml had no significant effect on MPO release by neutrophils activated with FMLP-CB in the presence or absence of 12.5 ,uM 1-hp. The results for systems containing neutrophils only, FMLP-CB, and FMLP-CB plus 1-hp were 1.9% + 1%, 17% + 7%, and 35% + 6% of total MPO release, respectively. The results for systems containing roxithromycin FMLP-CB and roxithromycin at 10 and 20 ,ug/ml were 16% + 6% and 16% + 6%.
Results for a system containing (10 ,ug/ml), FMLP-CB, and 1-hp and a system containing roxithromycin (20 ,ug/mI), FMLP-CB, and 1-hp were 39% ± 8% and 39% ± 5%, respectively.
DISCUSSION
Excessive neutrophil migration into the bronchial tree is a feature of bronchiectasis (8) , and neutrophils are present in increased numbers in purulent sputum obtained from patients with bronchiectasis. Pyocyanin and 1-hp are produced by P. aeruginosa strains which initially colonize the respiratory tract (35) . Both pigments are present in sufficient concentrations in sputum to affect neutrophil oxidative metabolism and degranulation, thereby enhancing the proinflammatory activities of these cells and increasing the potential threat of oxidant-mediated toxicity to bystander cells and tissues (31, 34) . Preventing either neutrophil migration into the bronchial tree or activation of these cells could modulate progression of bronchiectasis and other chronic inflammatory diseases associated with oxidant-mediated tissue damage.
It has previously been reported that erythromycin and clindamycin at supratherapeutic concentrations, as well as roxithromycin at both therapeutic and supratherapeutic concentrations, inhibit the generation of reactive oxidants by stimulus-activated neutrophils (1, 15, 18, 26, 32) . The inhibitory effects of the macrolide antibiotics are apparently selective for relatively weak stimuli such as those of FMLP and the calcium ionophore A23187, whereas they have little effect on the corresponding responses activated by opsonized particulate stimuli and the tumor promotor phorbol myristate acetate (1, 18) .
In this study, clindamycin, erythromycin (20 ,ug/ml), and roxithromycin (10 and 20 ,ug/ml) inhibited superoxide production by both pyocyanin-treated and untreated FMLPactivated neutrophils. Essentially similar effects were observed when calcium ionophore was used as the stimulus of membrane-associated oxidative metabolism. Roxithromycin was the most potent inhibitor of superoxide generation, probably as a consequence of the greater intraphagocytic accumulation of this agent relative to erythromycin and clindamycin (2, 16, 29) . Although the precise biochemical mechanism by which clindamycin, erythromycin, and roxithromycin inhibit superoxide generation by activated neutrophils has not been elucidated, the presently available data indicate that these agents affect the activity of NADPH- oxidase (1, 32) . This is supported by the absence of superoxide-scavenging properties in the test antimicrobial agents (1, 32) and the observation in the present study that roxithromycin impairs oxygen consumption by FMLP-activated neutrophils.
Unlike pyocyanin, 1-hp does not prime neutrophils for increased production of superoxide (31) . However, this agent causes potent enhancement of MPO-mediated iodination by priming neutrophils for increased release of primary granules following activation with FMLP. In the present study, the test antimicrobial agents did not interfere with the release of MPO by either untreated or 1-hp-primed neutrophils. However, these agents caused a dose-related inhibition of MPO-mediated iodination by neutrophils. The order of potency was roxithromycin > erythromycin and roxithromycin > clindamycin. These inhibitory effects of the macrolides and clindamycin on MPO-mediated iodinating activity of both control and 1-hp-primed neutrophils are probably due to interference with NADPH-oxidase activity, leading to inhibition of the generation of H202 and subsequent secondary inhibition of the MPO-H202-halide system. Aerobic gram-negative bacilli are uniformly resistant to clindamycin and macrolide antimicrobial agents. Consequently, these agents have no primary value in the chemotherapy of P. aeruginosa infections. However, if the proinflammatory effects of pyocyanin and 1-hp (31) are operative in vivo, the data presented here indicate a possible secondary role for agents such as clindamycin, erythromycin, and especially roxithromycin in the prevention of tissue damage inflicted by pigment-primed, activated neutrophils during the colonization of the respiratory tract with P. aeruginosa. Although this suggestion is speculative and requires rigorous investigation using models of experimental chemotherapy, combinations of clindamycin or macrolides with standard anti-Pseudomonas chemotherapeutic agents appear to satisfy some critical preliminary prerequisites. First, the possibility that clindamycin or macrolides interfere with the direct action of anti-Pseudomonas antibiotics has been examined. The aminoglycosides tobramycin and amikacin and the beta-lactam antibiotics piperacillin, ceftazidime, and imipenem were tested by a checkerboard technique, with each antibiotic in combination with either clindamycin, erythromycin, or roxithromycin against a pyocyanin-producing clinical isolate of P. aeruginosa. At concentrations achievable in the blood, no significant antagonism or synergism was found (unpublished data). These findings are in keeping with those of 
